Phibro Animal Health Corporation
Phibro Animal Health Corporation (Nasdaq: PAHC) develops, manufactures and markets animal health and mineral nutrition products for livestock producers, feed companies, veterinarians, distributors and other customers, as well as specialty ingredients for industrial markets. Its animal health portfolio includes… From the company’s description.
Over the twelve months to Sep 30, 2026, Phibro Animal Health Corporation reported revenue of $1.54B, up 10.1% from a year earlier, and net income of $102.71M. Its operating margin was 12.5%, and operations generated $85.73M in cash. In fiscal 2026, it reported revenue of $1.52B, up 17.1% from fiscal 2025, and net income of $99.72M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Phibro Animal Health Corporation does
In the company’s own words
Phibro Animal Health Corporation (Nasdaq: PAHC) develops, manufactures and markets animal health and mineral nutrition products for livestock producers, feed companies, veterinarians, distributors and other customers, as well as specialty ingredients for industrial markets. Its animal health portfolio includes antibacterials, anticoccidials, nutritional specialties and vaccines for poultry, cattle, swine and aquaculture, alongside products for companion animals and the ethanol industry. Mineral nutrition products provide trace minerals for animal feed, while Performance Products supplies ingredients to personal care, industrial chemical and chemical catalyst industries. The company reports three segments: Animal Health, which generated 77% of fiscal 2026 net sales; Mineral Nutrition, 19%; and Performance Products, 5%. Net sales totaled $1.518 billion for the year ended June 30, 2026. Phibro markets approximately 790 product lines in about 90 countries and serves roughly 4,800 customers. Its brands include Terramycin, Stafac, OmniGen, GemStone and TAbic. In October 2024, it acquired Zoetis’s medicated feed additive portfolio, certain water-soluble products and related assets.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- TEANECK, NJ
- Fiscal year end
- June
- CIK
- 1069899
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Phibro Animal Health Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Phibro Animal Health Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Phibro Animal Health Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Phibro Animal Health Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Phibro Animal Health Corporation's last four quarterly filings that the numbers alone won't show?”